<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00388609</url>
  </required_header>
  <id_info>
    <org_study_id>MB109-007</org_study_id>
    <nct_id>NCT00388609</nct_id>
  </id_info>
  <brief_title>Multiple-dose Study to Evaluate the Efficacy, Safety and Pharmacokinetics of BMS-646256 in Obese Subjects</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-Controlled, Parallel Arm, Multiple-Dose Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of BMS-646256 in Obese and High Risk Overweight Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Solvay Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to learn if BMS-646256 can cause weight loss in men and women
      who are:

        -  overweight with high blood pressure or high cholesterol or

        -  obese

      The safety of this treatment will also be studied
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>November 2006</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <primary_completion_date type="Actual">September 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent change in body weight from the start of the study</measure>
    <time_frame>Average of Week 11 and 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in body weight</measure>
    <time_frame>Average of Week 11 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BMI</measure>
    <time_frame>Change from baseline to Week 12, Week 32, and Week 44</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>waist circumference</measure>
    <time_frame>Change from baseline to Week 12, Week 32, and Week 44</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hormonal measures of insulin sensitivity and safety</measure>
    <time_frame>Percent change from baseline to Week 12, Week 32, and Week 44</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood pressure</measure>
    <time_frame>Change from baseline to Week 12, Week 32, and Week 44</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood lipids</measure>
    <time_frame>Change from baseline to Week 12, Week 32, and Week 44</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of adverse events and lab abnormalities</measure>
    <time_frame>throughout the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change and percent change in body weight</measure>
    <time_frame>at Week 32 from baseline and Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time-matched change from baseline in QTc</measure>
    <time_frame>at Week 12 and Week 32</time_frame>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">705</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>T</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 mg (ST) to 50 mg (LT)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>U</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 mg (ST) to 50 mg (LT)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>V</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>25 mg (ST) to 50 mg (LT)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>W</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 mg (ST and LT)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>X</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>25 mg/d (X1 wk), 5 mg/d (X11 wks) (ST) to 50 mg (LT)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Z</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Open label: 50 mg/d (X 4 wks) 100 mg/wk (X8 wks) (ST) to 50 mg (LT)
Once daily (x 4 weeks), once daily (x 8 weeks)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Y</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>0 mg (ST and LT)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-646256</intervention_name>
    <description>Tablet, Oral, Once Daily, 12 weeks treatment followed by 20 week washout (ST); up to 190 weeks treatment (LT)</description>
    <arm_group_label>T</arm_group_label>
    <arm_group_label>U</arm_group_label>
    <arm_group_label>V</arm_group_label>
    <arm_group_label>W</arm_group_label>
    <arm_group_label>X</arm_group_label>
    <arm_group_label>Z</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Tablet, Oral, Once daily, 12 weeks treatment followed by 20 week washout (ST); up to 190 weeks treatment (LT)</description>
    <arm_group_label>Y</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women, ages ≥18 to ≤70 years old with a Body Mass Index (BMI) ≥30 to ≤45 kg/m²
             OR BMI &gt;27 to &lt;30 kg/m² with hypertension and/or dyslipidemia defined as:

          -  Hypertension defined as treatment with an antihypertensive agent or mean systolic
             blood pressure ≥140 and ≤160 mmHg and/or diastolic blood pressure ≥ 90 and ≤ 105 mmHg

          -  Dyslipidemia defined as stable dose treatment with a statin, fibrate or ezetimibe for
             ≥ 6 weeks and/or triglycerides ≥ 150 and ≤ 600 mg/dL, LDL ≥ 130 and ≤ 300 mg/dL, or
             HDL &lt; 40 mg/dL

        Exclusion Criteria:

          -  Type 1 or 2 diabetes mellitus

          -  history of MI in the prior 6 months

          -  history of heart failure

          -  history of symptomatic arrhythmia

          -  active hepatic disease

          -  any documented muscle disease

          -  history of neurological symptoms or disease (including but not limited to tremor,
             ataxia, dizziness, neuropathy, or episodes of confusion, history of seizures, stroke
             or TIA)

          -  known history of major psychiatric conditions (e.g. schizophrenia anxiety disorder,
             dementia or bipolar disorder as defined by DSM IV criteria)

          -  history of depression or suicide attempt or ideation

          -  previous history of surgical procedures for weight loss (e.g., stomach stapling,
             bypass)

          -  uncontrolled blood pressure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ucla Center For Human Nutrition</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Domenica M. Rubino, Md</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Csra Partners In Health, Inc</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30909</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Springfield Diabetes And Endocrine Center</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pennington Biomedical Research Center</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70808</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Center For Nutrition &amp; Preventive Medicine, Pllc</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University Of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hampton Roads Center For Clinical Research Inc.</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Clinical Research, Inc.</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>For FDA Safety Alerts and Recalls refer to the following link www.fda.gov/MEDWATCH/safety.htm</description>
  </link>
  <verification_date>May 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 5, 2006</study_first_submitted>
  <study_first_submitted_qc>October 16, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 17, 2006</study_first_posted>
  <disposition_first_submitted>September 10, 2010</disposition_first_submitted>
  <disposition_first_submitted_qc>September 10, 2010</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">September 14, 2010</disposition_first_posted>
  <last_update_submitted>September 15, 2010</last_update_submitted>
  <last_update_submitted_qc>September 15, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 17, 2010</last_update_posted>
  <responsible_party>
    <name_title>Study Director</name_title>
    <organization>Bristol-Myers Squibb</organization>
  </responsible_party>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

